DÄ internationalArchive37/2006Early Detection of Prostate Cancer


Early Detection of Prostate Cancer

Dtsch Arztebl 2006; 103(37): A-2399

Börgermann, C; Rübben, H

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. De Koning HJ, Liem MK, Baan CA et al.: Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268–73. MEDLINE
2. Schmid HP, Riesen W, Prikler L: Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004; 50: 71–8. MEDLINE
3. Pienta KJ: Etiology, epidemiology and prevention of carcinoma of the prostate. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ, Hrsg.: Campell´s Urology. Philadelphia: Saunders, 1997: 2489–96.
4. Statistisches Bundesamt. www.destatis.de/basis/d/gesu/gesutab20.php
5. Fachgesellschaften (2002): AWMF: S3-Leitlinie: PSA-Bestimmung in der Prostatakarzinomdiagnostik (Früherkennung des Prostatakarzinoms). www.awmf-online.de.
6. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J: The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156: 127–32. MEDLINE
7. Luboldt H, Rubben H: PSA – Früherkennung des Prostatakarzinoms. Urologe A 2000; 39: 22–6. MEDLINE
8. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ: Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/mL or less. J Urol 1999; 161(3): 835–9. MEDLINE
9. Ellis WJ, Chetner MP, Preston SD, Brawer MK: Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994; 152: 1520–5. MEDLINE
10. Flanigan RC, Catalona WJ, Richie JP et al.: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol 1994; 152:1506–9. MEDLINE
11. Loch T, Leuschner I, Genberg C et al.: Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma. Urologe A 2000; 39: 341–7. MEDLINE
12. Loch T, Eppelmann U, Lehmann J, Wullich B, Loch A, Stockle M: Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 2004; 22: 357–60. MEDLINE
13. Brawer MK, Chetner MP: Ultrasonography and biopsy of the prostate. In: Walsh PC, Retik A, Stamey TA, Vaughan EJ, eds.: Campell´s Urology. Philadelphia: Saunders, 1997: 2506–18.
14. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schroder FH: Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60(5): 826–30. MEDLINE
15. Hoedemaeker RF, Rietbergen JB, Kranse R, Schroder FH, van der Kwast TH: Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 2000; 164(2): 411–15. MEDLINE
16. Catalona WJ, Smith DS, Wolfert RL et al.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20. MEDLINE
17. Luboldt HJ, Altwein JE, Bichler KH, Czaja D et al.: Early recognition of prostate carcinoma. Initial results of a prospective multicenter study in Germany. Project Group for Early Detection DGU-BDU Laboratory diagnosis Professional Circle. Urologe A 1999; 38(2):114–23. MEDLINE
18. Price CP, Allard J, Davies G et al.: Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 2001; 38(Pt 3):188–216. MEDLINE
19. Thompson IM, Goodman PJ, Tangen CM et al.: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215–24. MEDLINE
20. Carter HB, Epstein JI, Partin AW: Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53:126–30. MEDLINE
21. Catalona WJ, Loeb S: The PSA era is not over for prostate cancer. Eur Urol 2005; 48: 541–5.
22. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977–84. MEDLINE
23. Van der Cruijsen-Koeter IW, van der Kwast TH, Schroder FH: Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003; 95:1462–6. MEDLINE
24. Klotz L: Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172: 48–50. MEDLINE